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Abstract
Background: Multiple reviews demonstrated high variability in effectiveness and cost-effectiveness outcomes
among studies on breast cancer screening (BCS) programmes. No study to our knowledge has summarized the
current evidence on determinants of effectiveness and cost-effectiveness of the most used BCS approaches or tried
to explain differences in conclusions of systematic reviews on this topic. Based on published reviews, this
systematic review aims to assess the degree of variability of determinants for (a) effectiveness and (b) cost-
effectiveness of BCS programmes using mammography, clinical breast examination, breast self-examination,
ultrasonography, or their combinations among the general population.
Methods: We will perform a comprehensive systematic literature search in Cochrane, Scopus, Embase, and Medline
(via Pubmed). The search will be supplemented with hand searching of references of the included reviews, with
hand searching in the specialized journals, and by contacting prominent experts in the field. Additional search for
grey literature will be conducted on the websites of international cancer associations and networks. Two trained
research assistants will screen titles and abstracts of publications independently, with at least random 10% of all
abstracts being also screened by the principal researcher. The full texts of the systematic reviews will then be
screened independently by two authors, and disagreements will be solved by consensus. The included reviews will
be grouped by publication year, outcomes, designs of original studies, and quality. Additionally, for reviews
published since 2011, transparency in reporting will be assessed using the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) checklist for the review on determinants of effectiveness and a modified
PRISMA checklist for the review on determinants for cost-effectiveness. The study will apply the Assessing the
Methodological Quality of Systematic Reviews checklist to assess the methodological quality of systematic reviews.
We will report the data extracted from the systematic reviews in a systematic format. Meta-meta-analysis of
extracted data will be conducted when feasible.
Discussion: This systematic review of reviews will examine the degree of variability in the effectiveness and cost-
effectiveness of BCS programmes.
Systematic review registration: PROSPERO CRD42016050764 and CRD42016050765
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Background
Breast cancer screening (BCS) is a complex multidiscip-
linary approach that aims to reduce mortality from one
of the most common causes of cancer-related death
among women [1]. Different screening tests have been
used for implementing BCS programmes among the
general female population including breast self-
examination (BSE), clinical breast examination (CBE),
ultrasonography (US), and mammography.
Multiple country-level and international recommen-
dations have been developed to guide the implemen-
tation of BCS policies [2-6]. However, despite being
based on extensive evidence reviews, these docu-
ments recommend differently. For example, the Inter-
national Agency for Research on Cancer and the US
Preventive Service Task Force conclude on sufficient
evidence regarding the benefits of mammography for
50–74-year-old women [3, 4], the European Society
for Medical Oncology (ESMO) [2] for 50–69 years
old, the American Cancer Society [5] from the age of
45 and continuing after 69 if life expectancy is more
than 10 years, and the UK National Health Service
for women aged 50 to 70 years old every 3 years [6].
The other screening modalities are either seen as
lacking adequate evidence on mortality reduction by
the latest guidelines (for example, BSE and CBE) or
mainly recommended for high-risk population groups
or as diagnostic tools (for example, the US and
magneto-resonance imaging) [2–6].
BCS can achieve a decrease in mortality only if ap-
propriately implemented. But, even though effective-
ness (i.e. a mortality decrease) is the main
consideration for BCS adoption, cost-effectiveness of
screening modalities has become an integral part of
the decision-making process. Both clinical and eco-
nomic evaluations of BCS can be done as a trial or a
modelling study. While the former is a time- and
budget-consuming method, the latter frequently re-
quires sophisticated data and comprehensive statistics.
Since high-quality data related to effectiveness and
cost-effectiveness of screening programmes may not
be available in a country of interest, the targeted out-
comes may be approximated from other jurisdictions.
There are multiple reasons why effectiveness and
cost-effectiveness of screening interventions might dif-
fer between the countries, including variability in
implementation characteristics, healthcare capacity
and clinical practices, treatment adherences and
population preferences, demographic and epidemio-
logic characteristics, or unit prices. The International
Society for Pharmacoeconomics and Outcomes Re-
search Good Research Practices Task Force Report on
transferability defined that the parameters are called
generalizable if they are applied without adjustment
and transferable if they could be adapted to other
countries’ settings [7].
A considerable number of systematic reviews have
explored the effectiveness of BCS in terms of a reduc-
tion in mortality as well as the costs-effectiveness of
such programmes. These reviews demonstrated high
variability in types and values of outcomes which lead
to different conclusions and recommendations on the
most appropriate BCS strategy. For example, both re-
views from Hamashima et al. [8] and Lee et al. [9]
recommended mammography as a BCS modality,
while Nelson et al. [10] and Gøtzsche and Jørgensen
[11] concluded on small magnitude of benefits from
screening mammography comparing to the possible
harms.
Despite many reviews evaluating the quality of in-
cluded studies, to our knowledge, no study has sum-
marized the current evidence on the determinants of
effectiveness and cost-effectiveness of routinely used
BCS approaches or explored the possible differences
in the conclusions of systematic reviews on this topic.
It is also under question when the results of these re-
views can be applied to other countries of interests,
given the variability of data between the countries
and the studies. We propose a study synthesizing all
systematic reviews published until February 2017
reporting effect and efficiency characteristics of BCS
programmes.
Methods/design
The aim and objectives
This systematic review aims to assess the degree of vari-
ability and transferability of determinants of (a) effective-
ness (review 1) and (b) cost-effectiveness (review 2) of
BCS programmes using mammography, BSE, CBE, ultra-
sonography, or their combinations among the general
female population.
The specific research objectives are as follows:
(1)To summarize the evidence on the determinants of
effectiveness and cost-effectiveness of routine BCS
programmes
(2)To explore the variability in values of the
determinants of effectiveness and cost-effectiveness
between reviews and countries
(3)To explore the coherence of systematic reviews and
meta-analyses on the determinants of effectiveness
and cost-effectiveness
(4)To identify factors explaining the differences in
conclusions of the systematic reviews included in
this systematic review of reviews, if any observed
(5)To explore how the effect of the programme’s
characteristics as well as the country’s
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characteristics on determinants for effectiveness
and cost-effectiveness of BCS was investigated in
the systematic reviews
Study design
We designed the protocol in accordance with the
Cochrane handbook, personal rationale, and the Pre-
ferred Reporting Items for Systematic reviews and
Meta-Analyses Protocols (PRISMA-P) checklist (see
Additional file 1 for completed checklist) [12, 13].
The protocol of two reviews is registered with the
International prospective register of systematic re-
views (PROSPERO), the registration numbers are
CRD42016050764 (review 1) and CRD42016050765
(review 2) [14].
Eligibility criteria
The study will include systematic reviews that summarize
information on determinants of effectiveness (review 1)
and cost-effectiveness (review 2) of BCS. Systematic re-
views with any type of comparison group will be included
if they:
(a)Assess the following screening approaches: film
or digital mammography, ultrasonography, CBE,
or BSE
(b)Focus on a population of women older than 18 years
without symptoms of breast cancer and with an
average risk in this disease
(c)Use a systematic approach for literature search
using the preliminary specified inclusion/exclusion
criteria
(d)Conduct a literature search on more than one
country
(e)Provide an individual assessment and systematic
presentation of the characteristics and outcomes for
the included studies (forest-plot, table, or any other
structured data presentation)
(f ) Present the targeted primary or secondary outcomes
(g)Have a full-text publication
Since resource use and cost of breast cancer defines
cost-effectiveness of screening, reviews will be also in-
cluded if they (1) focus on a female population older
than 18 years old, diagnosed with breast cancer at
any stage and with average risk of disease progres-
sion; (2) include common treatment approaches
(containing surgeries, radiation, and pharmacological
interventions) used in actual clinical practice to treat
treatment-naïve, refractory, and relapsed patients
with breast cancer, and (3) assess the relevant pri-
mary or secondary outcomes.
We will exclude reviews that focus exclusively or in
combination on the following parameters: costs and
outcomes of co-morbidities of breast cancer, non-
screening technologies such as personalized medicine
or any original innovative treatment, non-traditional
medicines, hypnosis or psychological support, alter-
native treatments, herbal treatments, treatment of
sleep, sexual or emotional disorders, yoga, or other
practices typically not covered by the healthcare
system.
The primary outcomes for our review 1 are (1) ab-
solute and relative reduction in breast cancer, cancer,
and general mortality and (2) participation rate. Since
participation rates are frequently assessed in studies
examining interventions aimed at increasing adher-
ence to screening (interventions such as a standard
invitation letter, a call, or a combination of invitation
techniques), these reviews are also included. The sec-
ondary extracted outcomes for review 1 are incre-
mental breast cancer detection rate, size of detected
cancers, sensitivity of the screening programmes and
the test, recall rate, positive predictive value, number
needed to screen, and proportional internal cancer
rate.
The primary outcomes for our review 2 are (1)
mean direct BCS costs; (2) incremental cost-
effectiveness ratio, expressed as the cost per quality
adjusted life years in the baseline analysis; (3) incre-
mental cost-effectiveness ratio expressed in cost per
life-years gained in the baseline analysis; (4) total
costs of breast cancer, and (5) direct costs of breast
cancer. The secondary extracted outcomes for review
2 are median and/or mean direct, indirect and total
breast cancer and breast cancer screening costs,
costs for productivity loss related to breast cancer,
costs for informal care related to breast cancer, med-
ical resource use, non-medical resource use, average
duration of hospitalization, average number of hospi-
talizations per patient, average number of working
days lost, percentage of women receiving targeted
therapy and hormone stimulants, resources used re-
lated to breast cancer screening, life-years gained/
saved, quality adjusted life years, incremental cost-
effectiveness ratio in costs per cost per disability ad-
justed life years, and cost per death averted.
Search strategy
A comprehensive systematic search of “reviews” will be
conducted in Scopus, Embase, and Medline (via PubMed)
databases from inception to February 2017 with no lan-
guage restrictions. The search strategy for Medline via
PubMed is described in an additional document file (see
Additional file 2). The keywords “breast cancer AND
screening” are searched in the titles and abstracts of re-
views of the Cochrane database.
Mandrik et al. Systematic Reviews  (2017) 6:122 Page 3 of 6
In addition, the search will be augmented by iden-
tifying further studies from reference lists of identi-
fied relevant studies or reviews, by hand searching in
the specialized journals, and by contacting the prom-
inent experts in the field. A search for grey literature
will be conducted on the websites of the American
Society of Clinical Oncology (ASCO) [15], the
American Cancer Society [16], the International
Agency for Research on Cancer [17], and the ESMO
[18]. The additional search will include the keywords
“authors’ names AND breast cancer” in order not to
miss the updates of the conducted reviews and
search in PROSPERO database to identify if any re-
views are currently under development.
Data management
Systematic reviews obtained from the search are
exported to EndNote X8TM (Clarivate Analytics, Phila-
delphia, USA) where duplicates will be identified and re-
moved. Two trained research assistants will screen all
titles and abstracts of publications independently, with
at least 10% of all abstracts also screened by the princi-
pal researcher (OM). The full texts of publications will
be then screened for eligibility independently by the two
investigators. All disagreements will be solved by
consensus between the reviewers. Native speakers assist
with data extraction if an article is written in a language
other than English.
A data extraction sheet developed in Microsoft Excel®
2010 will be tested on two randomly selected studies. All
data will be extracted by one researcher and confirmed
by the second one. From each of the systematic reviews,
we will extract the general information (author(s), title,
years of publication and systematic search, targeted geo-
graphic search, and sponsorship), methods of systematic
review applied and methodology of studies included into
the reviews, the main reported information (the main
outcomes used, finding, conclusions, and limitations),
means, standard deviations, and ranges for primary and
secondary outcomes.
The references from the included publications will be
analysed if information from the systematic reviews is
incomplete to fill in the extraction sheet. Each review
will be assigned non-exclusively to the groups by (1) out-
comes presented, (2) year of publication (all the studies
and those published from 2011 and upward), (3) design
of the studies included into the reviews, and (4) quality.
The authorship, methods, and results sections of all
the included reviews will be explored in details to iden-
tify the following:
Duplicates: reviews published in different journals and
with possible differences in methods description, add-
itional/sub-group analyses, and/or data, but presenting
the same results for the main outcomes. We will include
the latest review if a duplicate is identified.
An update of another study: review-publications
updating previous reviews or fully including the results
of previously published reviews. All updates of the stud-
ies are included into data extraction, while only the lat-
est updated review will be combined into the summary
of the latest evidence.
Related publications: studies related to each other by
time and authorship, but presenting fully or partially dif-
ferent information. Each of the related publications will
be included into the analysis while being grouped in
clusters to address possible bias.
Quality appraisal
All included publications will be appraised by two inde-
pendent reviewers applying the Assessing the Methodo-
logical Quality of Systematic Reviews (AMSTAR)
checklist and considering selection, reporting, and publi-
cation biases [19]. For those studies that have been
judged to be of medium or high quality and which were
published after 2011, we will additionally assess the
transparency of reporting by using PRISMA checklist for
review on determinants of effectiveness and an adapted
PRISMA checklist to assess transparency of presentation
of the results in systematic reviews on costs and cost-
effectiveness of breast cancer screening (see Additional
file 3) [20]. Studies of medium or high quality published
before 2011 will remain for data synthesis only if no
other high-quality evidence for this outcome is available.
The disagreement between the reviewers on studies’
evaluations will be resolved by consensus and involve a
third party if consensus cannot be reached.
Data analysis
We will use Cohen’s kappa coefficient to define the
strength of agreement between the two evaluators. The
analyses reported in the included systematic reviews will
be extracted and reported in a systematic (table) format
together with reviews’ descriptive characteristics and
evaluations on their quality. A separate summary on
outcomes for each of the analysed subgroups will be
provided. We will discuss transferability of data from the
systematic reviews considering both quality of the
reviews and the included studies, transparency in report-
ing, geographic presentation in the reviews, variability in
outcome values reported by the reviews and systematic
differences in outcomes between countries.
Depending on the results of our systematic review of
reviews, primarily in relation to data heterogeneity, we
will also conduct meta-meta-analyses. For this, we will
select the reviews included with the relevant outcomes
and code their data for three age categories of women
(<49; 50–69; >70). We also aim to assess (1) an impact
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of the quality of the study on the results of meta-
analyses and (2) a difference in outcomes between the
designs of studies included into a systematic review. We
will apply a fixed effects model for those interventions
and population groups where heterogeneity is small and
a random effects model when heterogeneity leads to
higher I2 index considering possible variation in values
related to geographic differences in programme imple-
mentation, demographic, economic parameters, and
healthcare coverage. To address an overlapping of meta-
analyses, we will quantify the uniqueness of each of the
studies prior to meta-analyse the effect. The homogen-
eity of effect sizes will be assessed using a Q test.
Discussion
The decrease in mortality from breast cancer is the main
purpose of screening programmes. However, an evaluation
of the impact of screening must consider the organizational
structure of BCS delivery since the screening parameters
and populations are very heterogeneous given the differ-
ences in contextual factors between countries and significant
variations in the determinants of effectiveness and cost-
effectiveness in high- and low-income countries. Even with
similar performance characteristics (i.e. sensitivity and speci-
ficity) of BCS programmes, differences in programme attri-
butes such as demographic and structural parameters will
affect both outcomes and cost in different countries. Be-
cause of these variations, extrapolation of some of the deter-
minants of effectiveness and cost-effectiveness of BCS (e.g.
participation rates, treatment pathways, or unit costs of
screening implementation and cancer treatment) is difficult.
It is therefore important to carry out a systematic review
of reviews and critically summarize available evidence on
factors related to the impact of breast cancer screening on
population costs and health outcomes. This comprehensive
search is targeted to identify all published reviews and
meta-analyses on the effectiveness and cost-effectiveness of
BCS in high-, middle-, and low-income countries. It aims at
examining the reasons for differences between the reviews’
conclusions and recommendations, to explore how the
conclusions of systematic reviews evolved over time and
with new evidence and to summarize the latest evidence
based on systematic reviews with low risk of bias.
We use Cochrane’s definition of a systematic review [12]
and assess the methodological quality of systematic reviews
to limit the risk of bias using AMSTAR guidelines [19].
While these choices may limit the number of systematic re-
views that will be included in this systematic review of re-
views, it guarantees the best available evidence on which
we base the conclusions. The result of our systematic re-
view will summarize the available evidence on determinants
of effectiveness and costs of breast cancer screening pro-
grammes and define the needs for future research.
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